Skip to main content

Verzenio

Generic name: abemacicliba-BEM-a-SYE-klib ]
Drug class: CDK 4/6 inhibitors

Medically reviewed by Judith Stewart, BPharm. Last updated on Apr 21, 2023.

What is Verzenio?

Verzenio (abemaciclib) is a prescription medicine used in combination with other cancer treatments to treat certain patients with HR-positive, HER2-negative breast cancer. It is used in adults when the cancer has progressed or has spread to other parts of the body (metastatic) after other treatments have failed. Abemaciclib belongs to a class of medications called kinase inhibitors.

Verzenio is a targeted treatment known as a CDK4/6 inhibitor. It works inside the cell to block CDK4/6 activity and help stop the growth of cancer cells.

Verzenio is used in combination with an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer.

Verzenio is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor-positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body after treatment with an antiestrogen medication such as tamoxifen.

Verzenio is also used along with anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) as a first treatment of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body.

Verzenio is also used alone to treat a certain type of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body in people who have already been treated with an antiestrogen medication and chemotherapy.

Abemaciclib works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.

When Verzenio is used in combination with fulvestrant, tamoxifen, or an aromatase inhibitor, also read the Patient Information for the associated prescribed medicine. Ask your healthcare provider if you are not sure.

Warnings

Verzenio can cause severe diarrhea, which can lead to dehydration or infection. Call your doctor right away if you have diarrhea. Drink extra fluids and start taking anti-diarrhea medicine such as loperamide (Imodium).

Abemaciclib can cause blood clots, liver problems, and even serious or fatal infections. Call your doctor right away if you have symptoms such as: fever, chills, easy bruising or bleeding, unusual tiredness, loss of appetite, right-sided upper stomach pain, chest pain, shortness of breath, rapid breathing, fast heartbeats, or pain or swelling in your arms or legs.

Before taking this medicine

You should not use Verzenio if you are allergic to abemaciclib, or any of the ingredients in Verzenio tablets.

To make sure this medicine is safe for you, tell your doctor if you have ever had::

Abemaciclib may harm an unborn baby. You may need a pregnancy test to make sure you are not pregnant. Use effective birth control while using Verzenio and for at least 3 weeks after your last dose. Tell your doctor right away if you become pregnant.

It may be harder for you to get a woman pregnant while you are using this medicine.

You should not breastfeed while using this medicine and for at least 3 weeks after your last dose.

How should I take Verzenio?

Take Verzenio exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.

Take the medicine at the same time each day, with or without food.

Swallow the tablet whole and do not crush, chew, or break it. Do not use a cracked, broken or damaged tablet.

If you vomit shortly after taking Verzenio, do not take another dose. Take your next dose as scheduled.

Call your doctor if you have diarrhea while taking Verzenio. Start taking anti-diarrhea medicine such as loperamide (Imodium) to quickly treat diarrhea. Drink extra fluids and call your doctor.

Your blood will need to be tested often and your cancer treatments may be delayed based on the results.

Store at room temperature away from moisture and heat.

Verzenio dosing information

Usual Adult Dose for Breast Cancer:

IN COMBINATION WITH FULVESTRANT OR AN AROMATASE INHIBITOR:
150 mg orally 2 times a day

MONOTHERAPY:
200 mg orally 2 times a day

Duration of Therapy: Until disease progression or unacceptable toxicity

Comments:
-If using this drug in combination with fulvestrant on pre/perimenopausal women, treat these patients with a gonadotropin-releasing hormone agonist according to current clinical practice standards.
-When used in combination with this drug, the recommended dose of fulvestrant is 500 mg on Days 1, 15, and 29, then once monthly thereafter; refer to the manufacturer product information for fulvestrant.

Uses:
-In combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer
-In combination with fulvestrant for women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy
-As monotherapy for adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting

What happens if I miss a dose?

Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Verzenio?

Grapefruit may interact with abemaciclib and cause side effects. Avoid consuming grapefruit products.

Verzenio side effects

Get emergency medical help if you have signs of an allergic reaction to Verzenio: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Abemaciclib may cause serious side effects. Call your doctor at once if you have:

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common Verzenio side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Verzenio?

Sometimes it is not safe to use certain medicines at the same time. Some drugs can affect your blood levels of other drugs you use, which may increase side effects or make the medicines less effective.

Tell your doctor about all your other medicines, especially:

This list is not complete. Other drugs may interact with abemaciclib, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Ingredients

Active ingredient: abemaciclib
Inactive ingredients: microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide.
Color mixture ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, iron oxide red.

Manufacturer

Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA.

Popular FAQ

You will typically continue your Verzenio treatment until you have unacceptable side effects or the disease progresses. Do not stop taking your medicine or change your dose unless your doctor tells you to. Take Verzenio exactly as prescribed. Continue reading

Head-to-head trials comparing Verzenio to Ibrance have not been conducted. However, one is currently underway with results expected in 2023. Verzenio is taken twice daily, every day. Ibrance is taken every day for 21 days followed by a 7-day break. Verzenio can be used as monotherapy or in combination with other treatments. Ibrance is always taken in combination with either an aromatase inhibitor or fulvestrant. Verzenio is more likely than Ibrance to cause severe diarrhea. Both Verzenio and Ibrance can be used as combination treatment to treat breast cancer in men. Verzenio is also approved to treat adults with early breast cancer at high risk of recurrence in combination with endocrine treatment (tamoxifen or an aromatase inhibitor). Continue reading

Both Verzenio and Ibrance belong to the same class of medicine, called CDK 4/6 inhibitors, therefore, because they are both in the same class of medicines, clinically, it is unknown if there is an advantage in switching from one to another if one fails. However, research has shown breast cancer cells can acquire resistance to CDK 4/6 inhibitors by producing higher amounts of CDK6. Laboratory trials have shown that a “treatment holiday” of 28 days reversed this resistance, which implies that there may be some benefit of either stopping Ibrance temporarily or switching from Ibrance to Verzenio after a treatment break. Comparative trials comparing Verzenio to Ibrance are currently underway with results expected in 2023. Continue reading

Although Verzenio starts inhibiting CDK4/6 enzymes quickly, it may take up two to four months before any change in outcomes, such as progression-free survival, are noted. Side effects, such as diarrhea usually occur within the first week or month of treatment. Verzenio reaches consistent blood levels within five days of taking it twice a day.

Continue reading

Verzenio is considered a targeted treatment, rather than being a chemo drug, but it may be used to treat certain types of breast cancer. Verzenio belongs to the class of medicines known as CDK 4/6 inhibitors which help to reduce the growth and spread of cancer cells in the body. Continue reading

Trials have indicated that Verzenio plus endocrine therapy (ET) is more effective than ET alone at decreasing the risk of breast cancer recurrence and death by improving rates of invasive disease-free survival (IDFS). 4-year data from the monarchE trial showed 85.5% of patients remained recurrence-free after 4 years compared to 78.6% of those assigned ET alone (an absolute difference of 6.9%). Verzenio plus ET reduces the risk of recurrence by 35% compared to ET alone. Continue reading

Verzenio (abemaciclib) is a small molecule drug and kinase inhibitor used to treat patients with early breast cancer, and advanced or metastatic breast cancer. It is used to treat both men and women. Verzenio is an ATP-competitive inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4 and CDK6). Continue reading

View more FAQ

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Verzenio only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.